{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:40:01Z","timestamp":1756276801757,"version":"3.44.0"},"reference-count":25,"publisher":"BMJ","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DTB"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:p>Multiple sclerosis (MS) is a neurological condition that is estimated to affect around 60,000 people in England and Wales, with a lifetime risk in the UK of 1 in 1,000.<jats:sup>1,2<\/jats:sup> Spasticity (an increase in muscle tone) is a common symptom of MS, resulting in muscle spasms, immobility, disturbed sleep and pain.<jats:sup>3,4<\/jats:sup> Complex drug combinations are sometimes necessary to manage symptoms of MS, but these are often only partially effective and associated with unacceptable side effects.<jats:sup>5<\/jats:sup> Cannabis extract containing delta9-tetrahydrocannabinol (dronabinol) and cannabidiol are the principal extracts from the cannabis plant present in a licensed preparation (\u25bcSativex \u2013 GW Pharma Ltd), the first cannabinoid preparation to be approved for medical use. Sativex has been licensed \u201cfor symptom improvement in adult patients with moderate to severe spasticity due to MS who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy\u201d.<jats:sup>6<\/jats:sup> Here we review the evidence for cannabis extract and its place in the treatment of the condition. <\/jats:p>","DOI":"10.1136\/dtb.2012.11.0150","type":"journal-article","created":{"date-parts":[[2012,12,13]],"date-time":"2012-12-13T03:57:21Z","timestamp":1355371041000},"page":"141-144","source":"Crossref","is-referenced-by-count":0,"title":["What place for \u25bccannabis extract in MS?"],"prefix":"10.1136","volume":"50","member":"239","published-online":{"date-parts":[[2012,12,13]]},"reference":[{"key":"2025082623183358000_50.12.141.1","unstructured":"National Institute of Health and Clinical Excellence, 2003. Clinical guideline 8. Multiple sclerosis: national clinical guideline for diagnosis and management in primary and secondary care, 2003 [online]. Available: http:\/\/publications\u00a0nice.org.uk\/multiple-sclerosis-cg8\/guidance [Accessed 21 November 2012]."},{"key":"2025082623183358000_50.12.141.2","unstructured":"Multiple sclerosis. In: Longmore M Wilkinson I Turmezei T Cheung C (Eds). Oxford Handbook Clinical Medicine. Seventh edition. Oxford: Oxford University Press, 2007."},{"key":"2025082623183358000_50.12.141.3","unstructured":"Medicines and Healthcare products Regulatory Agency 2010. Public Assessment Report Decentralised Procedure Sativex Oromucosal Spray [online]. Available: http:\/\/www.cbg-meb.nl\/NR\/rdonlyres\/214BF38E-9F37-4C9B-AC0B-CFCB5EB3F421\/0\/SativexMHRAEPAR.pdf [Accessed 21 November 2012]."},{"key":"2025082623183358000_50.12.141.4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta7400","article-title":"Treatments for spasticity and pain in multiple sclerosis: a systematic review","volume":"7","author":"Beard","year":"2003","journal-title":"Health Technol Assess"},{"key":"2025082623183358000_50.12.141.5","doi-asserted-by":"publisher","DOI":"10.1191\/1352458504ms1082oa"},{"key":"2025082623183358000_50.12.141.6","unstructured":"Sativex oromucosal spray. Summary of Product Characteristics, UK. GW Pharma Ltd, October 2012."},{"key":"2025082623183358000_50.12.141.7","first-page":"CD001332","article-title":"Anti-spasticity agents for multiple sclerosis","volume":"4","author":"Shakespeare","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"2025082623183358000_50.12.141.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2008.05.011"},{"key":"2025082623183358000_50.12.141.9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2006.01639.x"},{"key":"2025082623183358000_50.12.141.10","doi-asserted-by":"publisher","DOI":"10.1038\/sj.sc.3101928"},{"key":"2025082623183358000_50.12.141.11","doi-asserted-by":"publisher","DOI":"10.2174\/138161208785740036"},{"key":"2025082623183358000_50.12.141.12","unstructured":"The Home Office, 2012. Drugs and the law [online]. Available: http:\/\/www.homeoffice.gov.uk\/drugs\/drug-law\/ [Accessed 21 November 2012]."},{"key":"2025082623183358000_50.12.141.13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1300\/J175v01n03_08","article-title":"Cannabis and cannabis extracts: greater than the sum of their parts?","volume":"1","author":"McPartland","year":"2001","journal-title":"J Cannabis Therapy"},{"key":"2025082623183358000_50.12.141.14","doi-asserted-by":"publisher","DOI":"10.1179\/016164109X12590518685660"},{"key":"2025082623183358000_50.12.141.15","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1468-1331.2010.03328.x","article-title":"A randomized, double-blind, placebo-controlled, parallel-group, enriched design sudy of nabiximols* (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis","volume":"18","author":"Novotna","year":"2001","journal-title":"Euro J Neurol"},{"key":"2025082623183358000_50.12.141.16","doi-asserted-by":"publisher","DOI":"10.1177\/1352458510367462"},{"key":"2025082623183358000_50.12.141.17","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1161\/CIRCULATIONAHA.108.809707","article-title":"Statistical Primer for Cardiovascular Research. Optimizing Trial Design","volume":"199","author":"Mehta","year":"2009","journal-title":"Circulation"},{"key":"2025082623183358000_50.12.141.18","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1212\/WNL.58.9.1404","article-title":"Safety, tolerability, and efficacy of orally administered cannabinoids in MS","volume":"58","author":"Killestein","year":"2002","journal-title":"Neurology"},{"key":"2025082623183358000_50.12.141.19","doi-asserted-by":"publisher","DOI":"10.1191\/0269215503cr581oa"},{"key":"2025082623183358000_50.12.141.20","unstructured":"The National Collaborating Centre for Chronic Conditions, 2004. Multiple sclerosis National clinical guideline for diagnosis and management in primary and secondary care [online]. Available: http:\/\/www.nice.org.uk\/nicemedia\/live\/10930\/46699\/46699.pdf [Accessed 21 November 2012]."},{"key":"2025082623183358000_50.12.141.21","unstructured":"National Institute of Health and Clinical Excellence, 2012. Multiple Sclerosis-Sativex [ID387] [online]. Available: http:\/\/guidance.nice.org.uk\/TA\/wave7\/34 [Accessed 21 November 2012]."},{"key":"2025082623183358000_50.12.141.22","unstructured":"Scottish Medical Consortium, 2011. Statement of Advice cannabinoid oromucsal spray Sativex no 703\/11 [online]. Available: http:\/\/www.scottishmedicines.org.uk\/files\/advice\/cannabinoid_Sativex_NON-SUBMISSION_FINAL_MARCH_2011_for_website.pdf [Accessed 21 November 2012]."},{"key":"2025082623183358000_50.12.141.23","unstructured":"Peninsular Health Technology Commissioning Group, 2011. Sativex for treatment of spasticity in multiple sclerosis [online]. Available: http:\/\/www.nelm.nhs.uk\/en\/NeLM-Area\/Evidence\/Drug-Specific-Reviews\/Sativex-for-treatment-of-spasticity-in-multiple-sclerosis2\/?query=sativex&rank=57 [Accessed 21 November 2012]."},{"key":"2025082623183358000_50.12.141.24","unstructured":"Joint Formulary Committee. British National Formulary. Edition 64. London: BMJ Group and RPS Publishing, September 2012."},{"key":"2025082623183358000_50.12.141.25","unstructured":"Royal Pharmaceutical Society, 2010. Sativex A Quick Reference Guide (member only content) [online]. Available: http:\/\/www.rpharms.com\/support-resources-a-z\/sativex-quick-reference-guide.asp [Accessed 21 November 2012]."}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2012.11.0150","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:18:54Z","timestamp":1756275534000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2012.11.0150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":25,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2012,12,13]]},"published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10.1136\/dtb.2012.11.0150"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2012.11.0150","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}